ADMA Biologics, Inc.

465 State Route 17 

Ramsey, New Jersey 07446

 

May 29, 2018

 

Via EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549-4561

 

Attn: Mary Beth Breslin

 

Re:

ADMA Biologics, Inc. (the “Company”) Registration Statement on Form S-3 Filed May 18, 2018, as amended File No. 333-225048

 

Dear Ms. Breslin:

 

The Company hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. (EST) on May 31, 2018, or as soon as practicable thereafter, pursuant to Rule 461 of the Securities Act of 1933, as amended.

 

The Company acknowledges that (i) should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

Please contact David C. Schwartz, Esq. of DLA Piper LLP (US) with any questions or comments at (973) 520-2555. Thank you for your assistance with this filing.

 

 

	ADMA BIOLOGICS, INC.
	By:	/s/ Adam S. Grossman
	Name:	Adam S. Grossman
	Title:	President and Chief Executive Officer